The panel of academic experts included 2018 Nobel Prize winner James P. Allison, Ph.D., of the University of Texas MD Anderson Cancer Center, Philip D. Greenberg, M.D., of the Fred Hutchinson Cancer Research Center, and Robert H. Vonderheide, Ph.D., D.Phil., of the University of Pennsylvania Abramson Cancer Center, all members of CRI’s Scientific Advisory Council.

ALSO ….

An industry fireside chat featured insights and opinions from Bristol-Myers Squibb’s Vice President, Head of U.S. Oncology Awny Farajallah, M.D., FACP, and Regeneron’s Founder, President, and Chief Scientific Officer George D. Yancopoulos, M.D., Ph.D. Meg Tirrell, biotechnology and pharmaceuticals reporter for CNBC moderated the industry panel and Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at the Cancer Research Institute, moderated the academic panel and provided an overview of CRI’s mission, programs, and impact over the past 65+ years.